Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds
出版年份 2022 全文链接
标题
Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-08-29
DOI
10.3389/fonc.2022.954806
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CCR5 is a potential therapeutic target for cancer
- (2021) Hossein Hemmatazad et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Healthy Volunteers in First in Human Oncology Drug Development for Small Molecules
- (2021) Begoña Heras et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
- (2020) Eric R. Fedyk et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Omiganan Enhances Imiquimod‐Induced Inflammatory Responses in Skin of Healthy Volunteers
- (2020) Tessa Niemeyer‐van der Kolk et al. CTS-Clinical and Translational Science
- Challenging the challenge: A randomized controlled trial evaluating the inflammatory response and pain perception of healthy volunteers after single-dose LPS administration, as a potential model for inflammatory pain in early-phase drug development
- (2020) H.J. Hijma et al. BRAIN BEHAVIOR AND IMMUNITY
- A Single and Multiple Ascending Dose Study of Toll‐Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers
- (2020) Andrea Luk et al. CTS-Clinical and Translational Science
- Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial
- (2020) Kasper Recourt et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade
- (2020) Yu-Chen Chuang et al. Frontiers in Immunology
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study
- (2020) Bruce A. Hug et al. CLINICAL THERAPEUTICS
- P2X7 in Cancer: From Molecular Mechanisms to Therapeutics
- (2020) Romain Lara et al. Frontiers in Pharmacology
- Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure
- (2020) Lilin Lai et al. Vaccines
- Immuno-oncology drug development forges on despite COVID-19
- (2020) Samik Upadhaya et al. NATURE REVIEWS DRUG DISCOVERY
- Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
- (2019) Maddalena Centanni et al. CLINICAL PHARMACOKINETICS
- Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases
- (2019) Yuan Cheng et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers
- (2019) Nandita Bose et al. JOURNAL OF IMMUNOLOGY
- Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
- (2019) Kirill Peskov et al. Frontiers in Immunology
- Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
- (2019) Stefanie R. Mullins et al. Journal for ImmunoTherapy of Cancer
- Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development
- (2019) Mariam A. Ahmed et al. CTS-Clinical and Translational Science
- The first clinical use of a recombinant Lactococcus lactis expressing human papillomavirus type 16 E7 oncogene oral vaccine: A phase I safety and immunogenicity trial in healthy women volunteers
- (2019) Amir Hossein Mohseni et al. MOLECULAR CANCER THERAPEUTICS
- The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
- (2019) Zuzanna Urban-Wojciuk et al. Frontiers in Immunology
- TYK2: An Upstream Kinase of STATs in Cancer
- (2019) Katharina Wöss et al. Cancers
- In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects
- (2018) Yan Li et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Targeting adenosine for cancer immunotherapy
- (2018) Robert D. Leone et al. Journal for ImmunoTherapy of Cancer
- No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects
- (2018) Manoli Vourvahis et al. JOURNAL OF CLINICAL PHARMACOLOGY
- TLR4-based immunotherapeutics in cancer: a review of the achievements and shortcomings
- (2018) Maryam A. Shetab Boushehri et al. MOLECULAR PHARMACEUTICS
- Interferon gamma in cancer immunotherapy
- (2018) Ling Ni et al. Cancer Medicine
- Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers
- (2018) Lisa Seitz et al. INVESTIGATIONAL NEW DRUGS
- Trends in the global immuno-oncology landscape
- (2018) Jun Tang et al. NATURE REVIEWS DRUG DISCOVERY
- CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
- (2018) Fabio Morandi et al. Frontiers in Immunology
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
- (2017) Christopher Banfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects
- (2017) Mayumi Mukai et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
- (2017) Darja Karpova et al. Journal of Translational Medicine
- Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics
- (2017) Kenneth C. Cassidy et al. XENOBIOTICA
- An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia
- (2017) Madhu Sanga et al. XENOBIOTICA
- Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females
- (2017) Masato Yokomine et al. Experimental and Therapeutic Medicine
- Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
- (2017) Palma Manduzio Therapeutics and Clinical Risk Management
- JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
- (2017) Chunwan Lu et al. OncoImmunology
- Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
- (2017) Weiqiang Zhou et al. CURRENT MEDICINAL CHEMISTRY
- CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma
- (2016) Colin W. Steele et al. CANCER CELL
- A Phase 1, double-blind, 4-period crossover study to investigate the effects of pomalidomide on QT interval in healthy male subjects
- (2016) Sabiha A. Mondal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy
- (2016) Hui Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- An FDA oncology analysis of immune activating products and first-in-human dose selection
- (2016) Haleh Saber et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells
- (2016) Yinghua Zhao et al. Nature Communications
- Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
- (2016) Thomas J. Hwang et al. JAMA Internal Medicine
- Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
- (2016) Idrian García-García et al. BMC Pharmacology & Toxicology
- Lenalidomide enhances myeloma-specific T-cell responsesin vivoandin vitro
- (2016) Isabelle Krämer et al. OncoImmunology
- Cancer immunotherapy trials: leading a paradigm shift in drug development
- (2016) Leisha A. Emens et al. Journal for ImmunoTherapy of Cancer
- Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
- (2015) S. Postel-Vinay et al. ANNALS OF ONCOLOGY
- The novel mechanism of lenalidomide activity
- (2015) E. C. Fink et al. BLOOD
- Risks of phase I research with healthy participants: A systematic review
- (2015) Rebecca A Johnson et al. Clinical Trials
- IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers
- (2015) Michelle L. Hernandez et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The changing landscape of phase I trials in oncology
- (2015) Kit Man Wong et al. Nature Reviews Clinical Oncology
- No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
- (2014) Nianhang. Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients
- (2014) A. Busch et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Pomalidomide: Evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects
- (2014) Claudia Kasserra et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men
- (2013) Nianhang Chen et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
- (2013) Catherine Dutreix et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response
- (2013) Lára Hannesdóttir et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Intracellular Poly(I:C) Initiated Gastric Adenocarcinoma Cell Apoptosis and Subsequently Ameliorated NK Cell Functions
- (2013) Jing Qu et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist
- (2013) Brian R Leaker et al. RESPIRATORY RESEARCH
- Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
- (2012) Adam del Corral et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity
- (2012) N. Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Use of Healthy Volunteers Drives Clinical Oncology Drug Development Decision Making
- (2012) M Iwamoto et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase I clinical trials of anticancer drugs in healthy volunteers: Need for critical consideration
- (2012) YogendraK Gupta et al. INDIAN JOURNAL OF PHARMACOLOGY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
- (2012) Yuan Xiao Zhu et al. LEUKEMIA & LYMPHOMA
- Pharmacokinetic Effects of Coadministration of Lersivirine with Raltegravir or Maraviroc in Healthy Subjects
- (2011) Manoli Vourvahis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers
- (2011) Steven J. Lemery et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects
- (2011) Nianhang Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of Vicriviroc With or Without Ritonavir on Oral Contraceptive Pharmacokinetics: A Randomized, Open-Label, Parallel-Group, Fixed-Sequence Crossover Trial in Healthy Women
- (2011) Claudia Kasserra et al. CLINICAL THERAPEUTICS
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- IL-3 is a novel target to interfere with tumor vasculature
- (2011) P Dentelli et al. ONCOGENE
- Effect of Vicriviroc on the QT/Corrected QT Interval and Central Nervous System in Healthy Subjects
- (2010) E. O'Mara et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers
- (2010) David J. Brooks et al. CLINICAL NEUROPHARMACOLOGY
- Distribution of Lenalidomide Into Semen of Healthy Men After Multiple Oral Doses
- (2010) Nianhang Chen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders
- (2010) Chaoshuang Lin et al. JOURNAL OF INFECTION
- BCR-ABL peptide vaccination in healthy subjects: Immunological responses are equivalent to those in chronic myeloid leukaemia patients
- (2010) José M. Rojas et al. LEUKEMIA RESEARCH
- Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: A randomized, crossover, double-blind study
- (2010) Idrian Garcia-Garcia et al. BMC Pharmacology & Toxicology
- SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects
- (2009) O. Holz et al. EUROPEAN RESPIRATORY JOURNAL
- The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers
- (2008) Samantha Abel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects
- (2008) John D. Davis et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/ zidovudine, and ethinyloestradiol/ levonorgestrel in healthy volunteers
- (2008) Samantha Abel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
- (2008) Samantha Abel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
- (2008) Samantha Abel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers
- (2008) Samantha Abel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
- (2008) Samantha Abel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started